Anixa Biosciences Inc

Anixa Biosciences is a biotechnology company focused on developing therapies and vaccines for oncology indications with unmet clinical needs. The company's therapeutic pipeline centers on liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy designed to treat ovarian cancer. This approach represents a variant of CAR-T cell technology. Additionally, Anixa is developing a breast cancer vaccine and operates a broader vaccine discovery program targeting intractable malignancies including lung, colon, and prostate cancers. The company's vaccine technologies focus on identifying retired proteins associated with various cancer types.

Anixa operates as a clinical-stage development company with limited revenue generation to date. The organization maintains a small operational footprint with four full-time employees and is headquartered in San Jose, California. The company was incorporated in Delaware in 1982, originally under the name ITUS Corporation before rebranding to Anixa Biosciences in October 2018. Its securities are listed on the Nasdaq exchange.